DeRxAI empowers Ontario pharmacists and family physicians to safely reduce polypharmacy in patients 65+—guided by Beers Criteria, STOPP/START, and Canadian deprescribing algorithms.
Process
DeRxAI turns complex polypharmacy reviews into structured, PDF-ready deprescribing plans—no manual chart trawling required.
Enter age, comorbidities, eGFR, frailty score, and current medications via form, CSV upload, or voice dictation. PHIPA-compliant with de-identification built in.
DeRxAI cross-references all medications against Beers Criteria 2025, STOPP/START v3, and Bruyère deprescribing algorithms via GPT-4 and Claude APIs.
Receive prioritized, cited recommendations with taper schedules, monitoring parameters, safer alternatives, and estimated annual cost savings in CAD.
Download PDF reports for EMR integration. Track implementation rates, outcomes, and cumulative savings across your patient panel on your dashboard.
Features
Dictate medication lists hands-free with continuous speech recognition. Supports fast, natural clinical workflows without slow manual typing.
Every recommendation cites Beers Criteria (AGS 2023/2025), STOPP/START v3, and Canadian Deprescribing Network algorithms—mandatory, inline, traceable.
Auto-generated dose reduction protocols (e.g. 25% per week) with safer non-pharmacological alternatives and patient monitoring checkpoints included.
Instantly estimates annual drug cost reductions in CAD per patient and across your practice panel, supporting business-case reporting to health networks.
Download structured, professional deprescribing reports optimised for direct attachment to patient charts in TELUS Health and other EMR systems.
Monitor cases reviewed, recommendations implemented, falls prevented, and cost savings across your panel with real-time admin-level charts and CSV exports.
Supported Clinical Frameworks
Sample Output
A 78-year-old frail female patient with 4 medications—DeRxAI identifies 2 high-priority reductions and estimates $1,550 CAD in annual savings.
Trust & Security
DeRxAI is designed from the ground up for clinical use—decision support only, not a SaMD device. The clinician remains responsible for every final decision.
De-identification of all PHI. No names or MRNs stored in production.
Mandatory PHIPA QI consent modal before any data is submitted.
Not classified as a SaMD. Clinician retains full diagnostic authority.
User accounts see only their own cases. Admin analytics anonymized.
PDF exports formatted for TELUS Health and other Ontario EMRs.
All API calls encrypted in transit. Validated schema before AI processing.
Pricing
Start your 2-week QI pilot free. No credit card required. Upgrade when you're ready to scale.
Join Ontario pharmacists and family physicians using DeRxAI to make evidence-based deprescribing decisions faster and safer.